Please try another search
Medigen Biotechnology Corp., a biopharmaceutical company, focuses on the development of therapies for liver diseases and cancers in Taiwan. It offers cell therapies, such as MAGICELL-NK, which are natural killer cells; and MAGICELL-GDT, which are T cells. It also develops OBP-301 that has completed Phase I clinical trials in combination with esophageal cancer in Japan; is in Phase I clinical trials in combination with immune checkpoint inhibitors (ICI) for patients with esophageal cancer in Japan; and in phase II study in combination with ICI for esophageal cancer and gastric cancer patients in the United States. Medigen Biotechnology Corp. was founded in 1999 and is headquartered in Taipei, Taiwan.
Name | Age | Since | Title |
---|---|---|---|
Shi-Chung Chang | 64 | - | Chairman |
Dun Mu Hong | - | - | Supervisor |
Min-Li Chuang | - | 2001 | Representative Director |
Jing Zhu Wu | - | - | Supervisor |
Tse Ling Chang | - | 2000 | Representative Director |
Pei-Wei Chen | - | 2021 | Independent Director |
Shang Yi Cai | - | - | Supervisor |
Shui-Ming Chuang | - | 2018 | Independent Director |
Tzu-Liang Huang | - | 2001 | Representative Director |
Por-Hsiung Lai | - | 2015 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review